Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Chinese Journal of Contemporary Pediatrics ; (12): 169-175, 2022.
Article in English | WPRIM | ID: wpr-928583

ABSTRACT

OBJECTIVES@#To systematically evaluate the effect of prophylactic use of hydrolyzed protein formula on gastrointestinal diseases and physical development in preterm infants.@*METHODS@#A computerized search was performed in the databases including China National Knowledge Infrastructure, Wanfang Data, Weipu, PubMed, Embase, and the Cochrane Library to identify randomized controlled trials of the effect of prophylactic use of hydrolyzed protein formula on gastrointestinal diseases and physical growth in preterm infants. RevMan 5.3 software was used to perform a Meta analysis for the included studies.@*RESULTS@#A total of 7 randomized controlled studies were included. The results of Meta analysis showed that compared with the whole protein formula, the prophylactic use of hydrolyzed protein formula could reduce the risk of neonatal necrotizing enterocolitis (RR=0.40, P=0.04) and feeding intolerance (RR=0.40, P=0.005), and had no significant effect on the growth of weight, length and head circumference (P>0.05).@*CONCLUSIONS@#Compared with the whole protein formula, the prophylactic use of hydrolyzed protein formula in preterm infants may reduce the occurrence of necrotizing enterocolitis and feeding intolerance, and can meet the nutrient requirement of physical development. However, the evidence is limited, and the results of this study cannot support the routine prophylactic use of hydrolyzed protein formula in preterm infants.


Subject(s)
Humans , Infant , Infant, Newborn , Enterocolitis, Necrotizing/prevention & control , Gastrointestinal Diseases/prevention & control , Infant Formula/chemistry , Infant, Low Birth Weight , Infant, Premature , Randomized Controlled Trials as Topic
2.
Chinese Journal of Contemporary Pediatrics ; (12): 446-453, 2020.
Article in Chinese | WPRIM | ID: wpr-828724

ABSTRACT

OBJECTIVE@#To assess the efficacy and safety of fluconazole in the prophylaxis of invasive fungal infection in very low birth weight (VLBW) infants.@*METHODS@#Databases including PubMed, Embase, the Cochrane Library, Wanfang Data, Weipu, and CNKI were searched for randomized controlled trials (RCTs) of prophylactic fluconazole in VLBW infants. Review Manager 5.3 software was used to perform a Meta analysis of the included studies.@*RESULTS@#A total of 12 RCTs were included, involving 1 679 VLBW infants. The Meta analysis showed that prophylactic fluconazole significantly reduced the incidence of invasive fungal infection (RR=0.44, 95%CI: 0.27-0.71, P0.05). No significant differences were found in the incidence of fluconazole resistance and complications between the fluconazole and control groups (P>0.05).@*CONCLUSIONS@#Prophylactic fluconazole can effectively and safely prevent invasive fungal infection in VLBW infants, even at a small dose.


Subject(s)
Humans , Infant, Newborn , Antifungal Agents , Fluconazole , Infant, Very Low Birth Weight , Invasive Fungal Infections
SELECTION OF CITATIONS
SEARCH DETAIL